Analysts await Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.14 EPS, up 71.43% or $0.1 from last year’s $-0.24 per share.

At the moment 12 analysts are watching Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), 2 rate it “Buy”, 3 “Outperform”, 6 “Underperform”, 0 “Sell”, while 1 “Hold”.

Looking forward, for the quarter ending Jun-16, 10 analysts have a mean sales target of 53.14 million. For the quarter ending Sep-16, 10 analysts have a mean sales target of 58.02 million whilst for the year ending Dec-16, 12 analysts have a mean target of 229.81 million.

In terms of earnings per share, 11 analysts have a -0.16 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 11 analysts have a -0.15 EPS mean target and for the quarter ending Sep-16 there are 12 estimates of -0.58 EPS.

The biggest institutional shareholders in Ironwood Pharmaceuticals, Inc. include Fidelity Management and Research Company which owns 19 million shares in the company valued at $224.53 million. Wellington Management Company LLP is the second biggest holder with 18 million shares currently valued at 206.05 million whilst Janus Capital Management LLC has 16 million shares valued at 182.67 million.

Total shares held by institutions as of the most recent company filings are 137,933,423 with a reported 7,151,556 bought and 30,824,829 sold. These holdings make up 96.23% of the company’s outstanding shares.

Currently insiders hold 7,080,417 shares in the business which makes up 4.94% of shares. The biggest holder currently is Mr. Edward P. Owens who owns 144,006 shares (0.10% of those outstanding), whilst Halley E. Gilbert holds 68,947 (0.05% of shares outstanding) and David E. Shaw holds 64,306 (0.04% of shares outstanding).

The stock decreased 1.28% or $0.13 during the last trading session.